PB2096: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT BTK INHIBITOR FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA AND PRIMARY VITREORETINAL LYMPHOMA
C. Soussain,
C. Grommes,
R. Ward,
C. Peterson,
M. Cravets,
A. Mathias,
J. Sosa,
B. Kirby,
Z. Ding,
I. Yusuf,
M. Rose,
M. Steinberg,
H. Tun
Affiliations
C. Soussain
1 Institut Curie, Saint-Cloud, France
C. Grommes
2 Memorial Sloan Kettering Cancer Center, New York, NY
R. Ward
3 Gossamer Bio, Inc., San Diego, CA
C. Peterson
3 Gossamer Bio, Inc., San Diego, CA
M. Cravets
3 Gossamer Bio, Inc., San Diego, CA
A. Mathias
3 Gossamer Bio, Inc., San Diego, CA
J. Sosa
3 Gossamer Bio, Inc., San Diego, CA
B. Kirby
3 Gossamer Bio, Inc., San Diego, CA
Z. Ding
3 Gossamer Bio, Inc., San Diego, CA
I. Yusuf
3 Gossamer Bio, Inc., San Diego, CA
M. Rose
3 Gossamer Bio, Inc., San Diego, CA
M. Steinberg
3 Gossamer Bio, Inc., San Diego, CA
H. Tun
4 Mayo Clinic, Jacksonville, FL, United States of America
